Biostar Pharma, Inc.
biostar-pharm.com
Commerce
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
华昊中天成立于2002年，2024年在香港主板上市（股票代码：2563.HK）。依托先进且可持续的合成生物学新药研发平台，专注于开发具有自主知识产权的抗癌新药，已成为集新药研发、生产和商业化为一体的整合型生物医药公司。.
News
Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. ("Biostar", Stock Code: 2563.HK) which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology
Read more
Report
Biostar Pharma, Inc.: Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
Read more
Report
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Beijing
China
HQ